Business
Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates
Initiated EQUATOR Phase 3 study of itolizumab in first-line aGVHD Acquired Bioniz Therapeutics, adding two first-in-class clinical-stage assets to pipeline
About this update from Equillium, Inc.
[{"type":"text","content":"\nInitiated EQUATOR Phase 3 study of itolizumab in first-line aGVHD\n\nAcquired Bioniz Therapeutics, adding two first-in-class clinical-stage assets to pipeline and proprietary product discovery platform\n\n LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the first quarter 2022 and provided an update on its corporate development and clinical programs.\n\n“It’s been a transformative start to the year, leading to significant enhancements in how we are building value going forward,” said Bruce Steel, chief executive officer at Equillium. “Since the beginning of the year we announced the acquisition of Bioniz Therapeutics, adding two first-in-class therapeutic candidates to our pipeline and an underlying novel drug discovery platform. This enables us to further expand our approach to business development and partnering efforts and significantly adds to our future operational milestones and pending data catalysts. In March we also announced the initiation of our Phase 3 EQUATOR study of itolizumab in first-line acute graft-versus-host disease and look forward to interim data from the Phase 1b EQUALISE study of itolizumab in patients with lupus nephritis expected mid-year.”\n\nClinical Highlights Since the Beginning of Q1 2022:\n\n\nInitiated Phase 3 EQUATOR study of itolizumab in first-line acute graft-versus-host disease (aGVHD), a randomized, double-blind global pivotal study assessing the efficacy and safety of itolizumab versus placebo as a first-line therapy for aGVHD in combination with corticosteroids that will enroll up to 200 patients. The primary endpoint assessment is complete response rate at Day 29, with key secondary endpoints of overall response rate at Day 29 and durability of complete response rate from Day 29 through Day 99.\n\n\nPublished data in the Journal of Clinical Investigation confirming the role of T cells activated by the CD6-ALCAM pathway in the development of lupus nephritis.\n\n\nCorporate Highlights Since the Beginning of Q1 2022:\n\n\nAcquired Bioniz Therapeutics, a privately held clinical-stage biotechnology company, significantly expanding the company’s pipeline of novel immunomodul...